A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD

Definitive discontinuation is defined as the date of first documentation of secukinumab discontinuation or biologic switch, whichever is recorded first.

Discontinuation due to lack of response is defined as the first documentation of secukinumab discontinuation or biologic switch due to lack of response or similar assessment, whichever is recorded first

PASI is a combined assessment of lesion severity and affected area into a single score. PASI scores can range from a lower value of 0, corresponding to no signs of psoriasis, up to a maximum of 72.0. The body is divided into 4 areas for scoring (head, arms, trunk, legs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area multiplied by the area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). A PASI 100 response corresponds to complete clearing of psoriasis (PASI = 0).

PASI is a combined assessment of lesion severity and affected area into a single score. The body is divided into 4 areas for scoring (head, arms, trunk, legs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area multiplied by the area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI scores can range from a lower value of 0, corresponding to no signs of psoriasis, up to a maximum of 72.0.

FIB-4 is a non-invasive tool used to assess liver fibrosis. The FIB-4 score is calculated using age, aspartate aminotransferase (AST) level, alanine aminotransferase (ALT) level, and platelet count.

FIB-4 fibrosis risk categories:

• Low risk: FIB-4 < 1.30
• Intermediate risk: 1.30 ≤ FIB-4 ≤ 2.67
• High risk: FIB-4 > 2.67

FIB-4 and aspartate aminotransferase to platelet ratio index (APRI) are non-invasive tools used to assess liver fibrosis. The scores are calculated using age, AST level, ALT level, and platelet count

FIB-4 fibrosis risk categories (patients aged ≥35 years):

• Low risk: FIB-4 < 1.30
• Intermediate risk: 1.30 ≤ FIB-4 ≤ 2.67
• High risk: FIB-4 > 2.67

APRI risk categories (patients aged <35 years):

• Low risk: APRI < 0.50
• Intermediate risk: 0.50 ≤ APRI ≤ 1.50
• High risk: APRI > 1.50

FIB-4 is a non-invasive tool used to assess liver fibrosis. The FIB-4 score is calculated using age, AST level, ALT level, and platelet count.

FIB-4 fibrosis risk categories:

• Low risk: FIB-4 < 1.30
• Intermediate risk: 1.30 ≤ FIB-4 ≤ 2.67
• High risk: FIB-4 > 2.67

APRI is a non-invasive tool used to assess liver fibrosis. The APRI score is calculated using AST level and platelet count

APRI risk categories:

• Low risk: APRI < 0.50
• Intermediate risk: 0.50 ≤ APRI ≤ 1.50
• High risk: APRI > 1.50

Associations between changes in the level of liver fibrosis (FIB-4) and changes in the severity of psoriasis (PASI) will be explored using Spearman correlations.

Associations between changes in the level of liver fibrosis (APRI) and changes in the severity of psoriasis (PASI) will be explored using Spearman correlations.